Meridian Bioscience completed the acquisition of Exalenz Bioscience for $49m.

Meridian Bioscience, an international producer and distributor of a range of diagnostic test kits, completed the acquisition of Exalenz Bioscience, a biotechnology company that develops and manufactures non-invasive diagnostic medical devices for gastrointestinal and liver conditions, for $49m. "We are excited to contribute our technology to the Meridian portfolio of H. pylori products and leverage Meridian’s strong commercial presence to accelerate the penetration of the BreathID® platform in the United States and beyond. We also look forward to collaborating with the Meridian R&D team in our on-going advancement of this leading platform," Raffi Werner, Exalenz CEO.